ClinicalTrials.gg
CompletedNCT00132639Updated Sep 22, 2016

Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Preoperative docetaxel-cisplatin combination chemotherapy and Preoperative docetaxel monotherapy in Pulmonary Neoplasms, sponsored by Haruhiko Fukuda. Completed at 1 site in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Haruhiko Fukuda · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Lung Neoplasms with a site in Japan — 27 open to participants now, 48 under way, 25 of them phase 3. Lung Neoplasms · Japan.

Enrollment
67th of 95
80 · median 200
Started
2002
the only one that year
Phase 2
21 of 102
5 open now
Registered
7th of 102
by date

Among the 102 studies in Lung Neoplasms with a site in Japan, this one is the 67th largest by enrollment of the 95 interventional ones that give a count, is the only one that started in 2002, is one of 21 in phase 2, and was the 7th registered.

Lung Neoplasms

5,434 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

27 of the 102 studies in Lung Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Lung Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of the preoperative docetaxel and docetaxel-cisplatin combination in c-stage IB/II NSCLC, and select the optimal preoperative therapy for phase III trials.

Read the detailed description

Preoperative chemotherapy has substantial theoretical advantage. Several controlled trials are under way in early stage (clinical stage IB-II) nonsmall cell lung cancer (NSCLC). In each trial, platinum-based doublet chemotherapy is employed. Although platinum-based doublet is the treatment of choice for advanced NSCLC, risk/benefit balance might well be different in earlier stages. There have been no prospective randomized trials to choose an optimal preoperative chemotherapy in early stage NSCLC.

Comparison: Preoperative cisplatin-docetaxel combination versus docetaxel monotherapy in clinical stage IB/II NSCLC.

03

Conditions studied

  • Pulmonary Neoplasms

Browse trials for

Keywords

  • pulmonary neoplasm
  • preoperative chemotherapy
  • cisplatin, docetaxel
  • randomized trial
  • clinical stage IB or II nonsmall cell lung cancer
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed, documented NSCLC
  • Clinical stages IB (T2N0M0), IIA (T1N1M0) or IIB (T2N1M0 or T3N0M0)
  • Ages: 15-74 years old
  • performance status 0 or 1
  • Ample organ function
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Invasion to the first rib or more superior chest wall
  • to, or involvement of, mediastinal node
  • Active concomitant
  • Unstable angina, recent myocardial infarction, or heart failure
  • Uncontrolled diabetes or hypertension
  • Pregnant or lactating women
  • Other severe complications
  • Systemic use of
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    1

    Preoperative docetaxel-cisplatin combination chemotherapy

    Drug: Preoperative docetaxel-cisplatin combination chemotherapy

  • Active comparator
    2

    Preoperative docetaxel monotherapy

    Drug: Preoperative docetaxel monotherapy

Interventions

  • DrugPreoperative docetaxel-cisplatin combination chemotherapy

    Preoperative docetaxel-cisplatin combination chemotherapy

  • DrugDocetaxelStudies of DocetaxelDocetaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Preoperative docetaxel monotherapy

06

What researchers measure

Primary outcomes

  1. disease-free survival rate at 1 year

    Time frame: during the study conduct

Secondary outcomes

  1. overall survival

    Time frame: during the study conduct

  2. disease-free survival

    Time frame: during the study conduct

  3. treatment compliance

    Time frame: during the study conduct

  4. response rate to chemotherapy

    Time frame: during the study conduct

  5. pathologic complete response (CR) rate

    Time frame: during the study conduct

  6. complete resection rate

    Time frame: during the study conduct

  7. post-surgical morbidity/mortality

    Time frame: during the study conduct

07

Study locations

1 site
  • National Cancer Center
    Chuo-ku,Tsukiji,5-1-1, Tokyo 104-0045, Japan
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2005
First posted
Aug 22, 2005
Start
Oct 2002
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00132639
Lead sponsor
Haruhiko Fukuda
Collaborators
Ministry of Health, Labour and Welfare, Japan
Responsible party
Haruhiko Fukuda (JCOG Data Center, Japan Clinical Oncology Group) — Sponsor-investigator
First posted
Aug 22, 2005
Start date
Oct 2002
Primary completion
Nov 2008
Completion
Nov 2008
Last update
Sep 22, 2016

Study contacts

Harubumi Kato, MD, PhD
study chair · Tokyo Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion